Nature Reviews Drug Discovery, Год журнала: 2025, Номер unknown
Опубликована: Апрель 25, 2025
Язык: Английский
The Lancet, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
1
Der Nervenarzt, Год журнала: 2025, Номер unknown
Опубликована: Март 5, 2025
Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide are glucagon-like peptide‑1 (GLP-1) receptor agonists. Tirzepatide targets not only GLP‑1 but also glucose-dependent insulinotropic peptide (GIP) receptors retatrutide is a triple GLP‑1, GIP glucagon agonist. The agonists increase insulin release suppress release. They slow down the emptying of stomach thus prevent blood sugar spikes. reduce appetite food intake. In brain lead to better glycemic control they appear have anti-inflammatory neuroprotective effects. It has been reported that oxidative stress apoptosis, lower risk ischemia promote neurogenesis. can influence dopaminergic signal transduction in nucleus accumbens. Therefore, could modify effect cocaine, alcohol nicotine. Preliminary investigations provide indications therapeutic benefits for people with dementia, eating disorders, psychopharmacologically induced weight gain, depression, anxiety substance use disorders. Typical accompanying adverse reactions gastrointestinal side effects, such as nausea, vomiting, diarrhea, eructation gastroesophageal reflux. More severe effects include pancreatitis, allergic reactions, renal function disorders possibly an increased thyroid cancer.
Язык: Английский
Процитировано
0
Frontiers in Aging, Год журнала: 2025, Номер 6
Опубликована: Март 20, 2025
Alzheimer’s disease (AD) is the most common age-related neurodegenerative and cause of dementia. AD pathology primarily involves formation amyloid β (Aβ) plaques neurofibrillary tangles containing hyperphosphorylated tau (p-tau). While Aβ targeted treatments have shown clinical promise, other aspects such as microgliosis, astrocytosis, synaptic loss, hypometabolism may be viable targets for treatment. Among notable novel therapeutic approaches, Ras homolog (Rho)-associated kinases (ROCKs) are being investigated treatment, based on observations that ROCK1/2 levels elevated in AD, activation or inhibition ROCKs changes dendritic/synaptic structures, protein aggregate accumulation, inflammation, gliosis. This review will highlight key findings effects ROCK ptau pathologies, well its neuroinflammation, density, potentially metabolism bioenergetics.
Язык: Английский
Процитировано
0
Journal of Neurology Neurosurgery & Psychiatry, Год журнала: 2025, Номер unknown, С. jnnp - 335593
Опубликована: Апрель 10, 2025
Disease-modifying treatments for major neurocognitive disorders, including Alzheimer’s disease, Parkinson’s disease and other cognitive deficits, are among the main unmet needs in modern medicine. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed treatment of type 2 diabetes mellitus obesity, offer a novel, multilayered mechanism intervention neurodegeneration through intermediate, aetiology-agnostic pathways, likely involving metabolic, inflammatory several relevant neurobiological processes. In vitro animal studies have revealed promising signals neuroprotection, with preliminary supportive evidence emerging from recent pharmacoepidemiological investigations clinical trials. this article, we comprehensively review that investigate impact GLP-1RAs on various aetiologies impairment dementia syndromes. Focusing human studies, highlight how brain energy homeostasis, neurogenesis, synaptic functioning, neuroinflammation cellular stress responses, pathological protein aggregates, proteostasis, cerebrovascular system blood-brain barrier dynamics may underlie GLP-1RA putative neuroprotective effects. We then report appraise observational investigations, trials pooled analyses. Finally, discuss current challenges perspectives ahead research implementation care people their individual penetrance potential, need response biomarkers stage-based indications, possible non-specific effects health, profile terms adverse events unwanted effects, lack long-term data efficacy safety, issues surrounding cost availability treatment.
Язык: Английский
Процитировано
0
Nature Metabolism, Год журнала: 2025, Номер unknown
Опубликована: Апрель 10, 2025
Язык: Английский
Процитировано
0
The Journal of Prevention of Alzheimer s Disease, Год журнала: 2025, Номер unknown, С. 100163 - 100163
Опубликована: Апрель 1, 2025
Following the recent approvals of anti-amyloid immunotherapies as "first-in-kind" disease-modifying agents for Alzheimer's disease (AD), there is an emerging emphasis in combination therapies, given complex and multifactorial etiopathogenesis pathophysiology disease. The EU/US CTAD Task Force met Madrid October 2024, to discuss biological rationale methodological issues outline potential directions future research therapies. agreed on necessity urgency advancing therapies AD treatment. As January 1, drug development pipeline, were 21 trials (13 % all trials). anti-tau could become a central focus field. Combinations involving anti-inflammatory immune mechanisms with or other also have promise. To facilitate implementation collaborations between sponsors public-private partnerships are essential. Optimizing likelihood success primarily requires leveraging use biomarkers clearer understanding underpinning their interactions, especially those amyloid, tau, inflammation, that lead cognitive decline progression.
Язык: Английский
Процитировано
0
Nature Reviews Drug Discovery, Год журнала: 2025, Номер unknown
Опубликована: Апрель 25, 2025
Язык: Английский
Процитировано
0